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Abstract   
Urotensin II (U-II) is the most potent vasoconstrictor known, even more potent than 
endothelin-1. It was first isolated from the fish spinal cord and has been recognized as a 
hormone in the neurosecretory system of teleost fish for over 30 years. After the 
identification of U-II in humans and the orphan human G-protein-coupled receptor 14 as the 
urotensin II receptor, UT, many studies have shown that U-II may play an important role in 
cardiovascular regulation. Human urotensin II (hU-II) is an 11 amino acid cyclic peptide, 
generated by proteolytic cleavage from a precursor prohormone. It is expressed in the central 
nervous system as well as other tissues, such as kidney, spleen, small intestine, thymus, 
prostate, pituitary, and adrenal gland and circulates in human plasma. The plasma U-II level 
is elevated in renal failure, congestive heart failure, diabetes mellitus, systemic hypertension 
and portal hypertension caused by liver cirrhosis. The effect of U-II on the vascular system is 
variable, depending on species, vascular bed and calibre of the vessel. The net effect on 
vascular tone is a balance between endothelium-independent vasoconstriction and 
endothelium-dependent vasodilatation. U-II is also a neuropeptide and may play a role in 
tumour development. The development of UT receptor antagonists may provide a useful 
research tool as well as a novel treatment for cardiorenal diseases. 
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Introduction 
Urotensin II (U-II) was first isolated from the fish spinal cord and has been recognized as a 
hormone in the neurosecretory system of teleost fish for over 30 years.1,2 U-II is the most 
potent vasoconstrictor known and is even more potent than endothelin-1 (ET-1).2 This brief 
review summarises what is known about the peptide and its receptor (UT), their physiological 
roles and relation to diseases. 
 
Amino acid sequence and mRNA expression 
U-II is a cyclic peptide and shares a similar sequence with somatostatin (Table 1).1 U-II 
isoforms from human, monkey, pig, rat, mouse and goby all contain a conserved C-terminal 
cyclic hexapeptide sequence (Cys-Phe-Trp-Lys-Tyr-Cys) that confers most of the biological 
activity. The N-terminus of U-II differs in length and sequence depending on the animal 
species.3,4 
 
Human U-II (hU-II) is an 11 amino acid cyclic peptide and is derived from a large precursor 
molecule (prepro-U-II). The gene encoding the peptide, UTS2, is located at 1p36 and contains 
5 exons (Figure 1). Human prepro-U-II mRNA has been found in the heart, aorta, vascular 
endothelial cells, leukocytes, brain, spinal cord, kidney, lung, liver, adrenal gland, pituitary, 
spleen, small intestine, colon, placenta and other tissues, with the highest intensity in the 
spinal cord.5-9 
 
Receptor structure and expression 
The receptor for hU-II turned out to be the orphan G-protein-coupled receptor 14 
(GPR14).2,10 This receptor, now termed UT, is a 389-amino acid protein with seven 
transmembrane domains. It is homologous to rat GPR14 and is similar to the somatostatin 
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receptor sst4 in structure.2,10 The gene coding for the human UT receptor is intronless and is 
located at 17q25.3.11 The UT receptor is found in human brain, spinal cord, leukocytes, 
ventricular myocardium, vascular endothelial and smooth muscle cells, kidney cortex, 
adrenal gland, pituitary and thyroid, with the highest density in skeletal muscle and cerebral 
cortex.2,6,7,9,12 The distribution of U-II and its receptor suggests that U-II may act as a local or 
circulating vasoactive hormone in cardiovascular regulation. Differential distribution of UT 
receptors may partly explain the variability in contractile responses to U-II. U-II was 
previously thought to be arterioselective because UT receptors have not been found in human 
veins except umbilical veins.2,10 More recent studies showed that hU-II contracts epigastric, 
facial, saphenous and umbilical veins, suggesting the presence of the UT receptor.12,13 
 
Signal transduction 
The UT receptor is coupled to the Gαq/11 signal transduction pathway, the activation of which 
leads to an increase in inositol triphosphate and mobilization of intracellular Ca2+ (Figure 
2).2,14,15 The mechanism by which U-II elicits smooth muscle contraction is complex.16,17 It 
involves small GTPase RhoA and its downstream effector Rho-kinase18, phospholipase C, 
protein kinase C and tyrosine kinase19, PKC-independent phosphylation of myosin light chain 
(MLC-2)20 as well as the Ca2+-calmodulin/MLC kinase system, extracellular signal-regulated 
kinase (ERK) and p38 mitogen-activated protein kinase.21 Rho signalling pathway and ERK 
may also be involved in U-II-induced vascular smooth muscle cell proliferation.18,22 
 
Post-translational processing of U-II  
Human prepro-U-II, first cloned by Coulouarn et al.3, has a signal-peptide sequence at the N-
terminal end (Figure 1). There are two alternative splicing variants of human prepro-U-II, 
isoforms a and b, with 139 and 124 amino acid residues respectively. They differ in the N-
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terminal sequence.2,3,4 Mature U-II is produced from the proteolysis of prepro-U-II at the 
putative tribasic site, K126K127R128, in the splice variant a and K111K112R113 in the splice 
variant b (Figure 1).2,3 The enzymatic cleavage confers biological activity.23 A specific 
urotensin converting enzyme (UCE) has not been identified, but there are several enzymes 
that can perform the proteolytic cleavage. By studying the conversion of a 25-amino acid C-
terminal fragment of prepro-U-II to mature U-II, Russell et al.24 demonstrated that furin, an 
endoprotease which is expressed in most cell types and localized in the trans-Golgi network25, 
may function as an intracellular UCE. The same authors also showed that trypsin, a serine 
protease, may act on prepro-U-II in the circulation.24 
 
U-II-like immunoreactivity 
As both prepro-U-II and mature U-II contain the Cys-Phe-Trp-Lys-Tyr-Cys cyclic motif, 
polyclonal antibodies may recognise other peptides containing this cyclic motif such as 
urotensin II-related peptide (URP) (Ala-Cys-Phe-Trp-Lys-Tyr-Cys-Val) (Table 1). URP is 
thought to be as the only peptide with U-II-like immunoreactivity in the rat brain and may be 
the endogenous ligand for the UT receptor in rat brain.8,26 The seven C-terminal residues of 
URP are identical to those in hU-II. This may explain the large variations in the estimation of 
U-II-like immunoreactivity in different studies.8,23,27 Human URP is derived from a 119-
amino acid residue precursor protein encoded by a gene at 3q29, so the gene and the 
precursor are different from those of hU-II.8,26 Although the physiological and pathological 
importance of URP is unknown at presence, URP exhibits a slightly higher affinity for the 
human UT receptor and a slightly lower potency in the contraction of de-endothelialized 
aortic rings.8,26,28 
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Reverse-phase HPLC and radioimmunoassay of brainstem and spinal cord extracts contains 
additional U-II-immunoreactive peaks, which may be due to cleavage of prepro-U-II at two 
other putative sites (Arg84Lys85 and Arg100Lys101 in splice variant a and Arg69Lys70 and 
Arg85Lys86 in splice variant b) (Figure 1).29 It is not known whether cleavage at these sites 
has any functional importance or is simply a process of protein degradation. Similar results 
were also observed in cultured human SW-13 adrenocortical carcinoma cells.30 The anti-hU-
II antibody cross-reacts with prepro-hU-II fragment.23 Even using more specific monoclonal 
antibodies, Aiyar et al.27 still found cross-reactivity and advised the cautious interpretation of 
U-II-like immunoreactivity.  
 
Analogues of U-II and their properties 
Analogues of U-II have been used to study the relationship between structure and function. 
The cyclic octapeptide, hU-II(4-11) generated by elimination of the Glu-Thr-Pro tripeptide in 
the N-terminal has a higher affinity to the UT receptor and higher vasoconstriction activity on 
the rat thoracic aorta than its full-length.19 Thus, residues 4-11 confer biological activity and 
are conserved across species while the N-terminus confers species specificity.19 The residues, 
Trp7-Lys8-Tyr9 appear to be essential for biological activity.31,32,33 Kinney et al.32 suggested 
the presence of a tyrosine-binding pocket in the UT receptor and the substitution of Tyr9 with 
(2-naphthyl)-L-alanine in U-II can improve the agonist activity slightly, perhaps due to 
enhanced hydrophobic interaction. The Phe6 of U-II may also interact with Met184 and 
Met185 of the fourth transmembrane domain of the UT receptor.34 The disulphide bridge of 
U-II is not essential for biological activity, as it can be replaced by a lactam ring.35 The 
replacement of Cys5 by penicillamine in hU-II(4-11) generates a potent agonist that has a 3-
fold higher affinity for the receptor and 20-fold more potent in contracting the rat aorta than 
full-length hU-II36. Camarda et al.37 generated a partial UT receptor agonist by replacing Lys8 
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with Orn. This [Orn8]U-II acts as a full agonist in calcium mobilization assay with a maximal 
effect similar to U-II, but acts as a competitive antagonist in the rat aorta assay, with a small 
and consistent residual agonist activity at high concentration.37 Urantide ([Pen5, DTrp7, 
Orn8]hU-II(4-11)) is the most potent antagonist in the rat aorta assay but an agonist in the 
calcium mobilization assay in cultured CHO cells transfected with the human UT 
receptor.38,39 
 
Based on the sequence similarity between U-II and somatostatin, Rossowski et al.19 reported 
that somatostatin analogues PRL-2882, PRL-2903 and PRL-2915 can act as rat UT receptor 
antagonists. The somatostatin antagonist, SB-710411, is also a rat UT receptor antagonist.40 
However, it potentiates the contractile response to endothelin-1, limiting its usefulness in 
pharmacological experiments.41 Interestingly, it is a full agonist at both monkey and human  
UT receptors, indicating that the functional response to UT receptor modulators may vary 
with species.42,43 The neuromedin B receptor antagonist, BIM-23127, with sequence 
similarity to SB-710411, has also been identified as a potent competitive antagonist of both 
human and rat UT receptors.44  
 
The development of UT receptor antagonists can advance the understanding of the 
pathophysiological role of U-II and the design of new drugs. Using a functional mammalian 
cell-based assay to screen a library of 180,000 small organic molecules, a highly selective 
non-peptide human UT receptor agonist with an EC50 of 300nM, AC-7954, was discovered.45 
Using a pharmacophore model based on the structure-function relationship data and the NMR 
solution structure, Flohr et al.31 identified by virtual screening 10 out of 500 compounds that 
can inhibit U-II induced calcium mobilization. Clozel et al.46 reported a new potent and 
specific non-peptide UT receptor antagonist, palosuran (ACT-058362) which can inhibit U-
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II-induced calcium mobilization, mitogen-activated protein kinase phosphorylation and 
constriction of rat aortic rings without any antagonistic effect on the actions of other 
vasoconstrictive agents. Intravenous administration of palosuran in a rat model of renal 
ischaemia improved renal glomerular and tubular dysfunction.46 Clinical studies of palosuran 
in renal diseases are currently in progress. 
 
Role in the cardiovascular system 
In human, hU-II can cause the vasoconstriction of coronary, mammary and radial arteries as 
well as saphenous and umbilical veins.12 It is about 50 times more potent than ET-1 in 
causing contraction of these arteries and just under 10 times more potent than ET-1 in 
contracting veins. However, the maximum response is significantly lower than that achieved 
by ET-1, and approximately 30% of coronary and mammary arteries respond to ET-1 but not 
to U-II.12 This may be due to the low density of high-affinity receptor in vascular smooth 
muscle cell of these vessels. The contractile effect of U-II, like ET-1, is of slow onset and 
long duration when compared with other vasoactive agents such as potassium chloride, 
noradrenaline and angiotensin II.13,47,48 The UT receptor is involved because isolated thoracic 
aortic rings from UT receptor knockout mice do not respond to hU-II.49 
 
U-II causes vasoconstriction in rat pulmonary artery but not the small pulmonary arteries of 
both rat and human.50 The effect is enhanced by endothelium removal, raised vascular tone, 
nitric oxide (NO) synthase inhibition and in pulmonary hypertension.50 However, Bennett et 
al.51 did not find any vasoconstrictive activity of U-II in isolated perfused human lungs and 
isolated human pulmonary arteries in endothelial dysfunction.  
 
 8
The vascular actions of U-II vary with species, vascular beds and even regions of the same 
vascular beds.13,52,53,54,55 U-II does not have any effect on human small subcutaneous 
resistance arteries and veins, human skeletal muscle small resistance arteries or mouse 
isolated thoracic and abdominal aortae.52,53,54 
 
The species and regional variations of U-II responses may be due to differences in receptor 
density, enzymatic conversion of the peptide, and the activity of endothelium derived 
relaxing factors, in which receptor density seems to be the predominant factor. U-II contracts 
rat thoracic aorta much more than abdominal aorta which is related to the higher UT receptor 
density in rat thoracic aorta as demonstrated by radioligand binding assay and RT-PCR.53,56,57 
The human coronary artery has a lower receptor density compared to rat aorta and this may 
account for the greater effect of U-II on the rat aorta compared to human coronary artery in 
vitro.12 Douglas et al.53 argued that the effect of endothelium derived relaxing factors could 
not explain the variations of U-II response in in vitro studies as regional and species 
differences still exist in endothelium-denuded vessels and instead suggested a spare receptor 
reserve hypothesis. In this hypothesis, most of the UT receptors are occupied by U-II in a 
“pseudo-irreversible manner” with a very slow receptor dissociation rate. Thus when there is 
a lack of spare receptor reserve, there may only be a small number of unoccupied UT 
receptors available for binding U-II. In such tissue, the response could be very variable or 
low. Moreover, different extent of UT receptor desensitization in different species or tissues 
may also contribute to the regional and species variations of U-II response. 
 
Human U-II induces a biphasic response in perfused rat heart, a transient decrease in 
coronary flow followed by sustained vasodilatation that can be inhibited by a cyclooxygenase 
inhibitor and an NO synthase inhibitor.58 Endothelium-dependent vasodilation was also 
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observed in methoxamine-precontracted small mesenteries arteries and phenylephrine-
precontracted renal artery57,59, and ET-1-precontracted small pulmonary arteries and 
abdominal resistance arteries.55 This might be due to the release of the NO or endothelium-
derived hyperpolarizing factor from an intact endothelium.50,57 NO plays an important role in 
the regulation of cardiac function and vascular tone.60 It is possible that the vasoconstricting 
effect of U-II is unmasked in endothelial dysfunction in which NO production is impaired. U-
II upregulates endothelial nitric oxide synthase (eNOS).61 In rat renal artery, hU-II induces 
NO synthesis in the intact endothelium, resulting in vasodilatation.59 
 
U-II also exhibits cardiostimulant effects in human heart in vitro.62 In a concentration-
dependent manner, hU-II increases the contractile force without changing the contraction 
duration in right atrial trabeculae from non-failing hearts, and causes a small increase in 
contractile force in right ventricular trabeculae from explanted hearts.62 It also enhances 
plasma extravasation in specific vascular territories, and may therefore be involved in the 
development of oedema in heart failure.63 
 
A biphasic haemodynamic response was observed after bolus injection of hU-II in conscious 
rats.64 The initial response was a prostanoid-mediated mesenteric and hindquarter 
vasodilatation, tachycardia and a small fall in blood pressure. After 30-60 min of injection, a 
second phase response was observed, including tachycardia and NO-dependent hindquarters 
vasodilatation with a modest rise in blood pressure.64,65  
 
Intravenous administration of U-II at low dose (<30pmolkg-1) in anaesthetized monkeys 
increases cardiac output and reduces peripheral resistance while a higher dose decreases 
myocardial function, cardiac output, stroke volume, heart rate, carotid and coronary blood 
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flow with an increase in vascular resistance which culminates in severe pulmonary 
hypertension, myocardial depression and fatal circulatory collapse.2,66 In anaesthetized rats, 
intravenous bolus hU-II injection decreases cardiac contractility, mean arterial blood pressure 
and left ventricular systolic pressure.67 Recently, the cat has been found to be a useful model 
to study as isolated feline arteries are highly responsive to U-II.68 Infusion of U-II in the cat 
doubles the systemic vascular resistance and blood pressure without marked changes in the 
heart rate or cardiac output.68  
 
In vivo, U-II causes potent vasoconstriction in man with a dose-dependent reduction in 
forearm blood flow.69 However, in another study, an increase in blood pressure or peripheral 
resistance was not observed following the infusion of U-II in healthy men.70 Moreover, 
intravenous U-II infusion did not affect systemic haemodynamics or arterial stiffness, even 
with a 100-fold increase in plasma U-II levels.71 As U-II can cause both endothelium-
independent vasoconstriction and endothelium-dependent vasodilatation, the net effect can be 
variable, depending on the balance between vasoconstriction and vasodilatation. In the 
studies of Wilkinson et al.70 and Affolter et al.71, the vasodilatation effect of U-II may mask 
its vasoconstriction effect. The vasoconstriction effect in the study of Bohm et al.69 may 
probably due to possible loss of vasodilator capacity and loss of NO. This loss of vasodilator 
capacity has been observed in the skin vessels heart failure patients, which may be due to 
endothelial dysfunction.72  
 
Role in the kidney 
In fish, U-II affects sodium transport, lipid and glucose metabolism.1 The urinary hU-II 
concentration is about 3 orders of magnitude greater than the plasma concentration.5 U-II 
may play a role in the regulation of GFR via the tubuloglomerular feedback and the reflex 
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control of glomerular filtration rate (GFR).73 In the kidney, U-II has vasodilator and 
natriuretic effects. Increases in renal blood flow and GFR were observed after the infusion of 
synthetic hU-II into the renal artery of anesthetized rats and this can be completely inhibited 
by a nitric oxide synthase inhibitor.59  
 
Role in the nervous system 
The presence of U-II-like immunoreactivity and the UT receptor in the motor neurons in the 
spinal cord and the brain stem suggests a potential role of U-II in the central nervous 
system.3,6,10 Prepro-U-II expression in the ventral horn of the spinal cord and facial nucleus 
motor neurons is reduced in neurons expressing androgen.74 How androgen interferes with U-
II expression is unclear but androgen can cause the promotion of motor neuron growth and 
regeneration as well as the prevention of normally occurring cell death in the sexually 
dimorphic spinal nucleus.75,76,77 
 
hU-II is interestingly expressed in the motor neurons of the human spinal cord motorneurons, 
like calcitonin gene-related peptide.3,78 U-II stimulates spontaneous neurotransmitter release 
from the motor nerve terminal in frogs.79 U-II induces c-fos in the cingulate cortex and 
periaqueductal grey.80 These areas integrate cognitive and emotional responses, and control 
motor, endocrine and autonomic functions. Intracerebroventricular (ICV) administration of 
hU-II in rats increased rearing and grooming, and motor activity as well as the plasma levels 
of thyroid stimulating hormone and prolactin without changing the levels of dopamine or 
serotonin (5-HT) levels, showing that U-II has behavioural and endocrine effects in the 
central nervous system.81 
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Intracerebroventricular administration of U-II elicits a pressor and tachycardic response via 
activation of the sympathetic nervous system.82 hU-II has different effects in different parts of 
the brain. Microinjection of U-II into the A1, but not A2 area of the rat medulla causes a dose-
dependent hypotensive and bradycardiac response while microinjection into either the 
paraventricular or arcurate nucleus increases the arterial blood pressure and heart rate slightly 
and transiently.83 In conscious unstressed sheep, intracerebroventricular administration of U-
II leads to secretion of adrenocorticotropic hormone (ACTH) and epinephrine by stimulating 
the sympathoadrenal medullary and the hypothalamic-pituitary-adrenal axes.84 This is then 
accompanied by increased cardiac output, raised arterial pressure, peripheral vasodilatation 
and hyperglycemia. In contrast, intravenous administration of U-II produces only a positive 
chronotropic effect.84 
 
Whereas U-II causes Ca2+ influx from intracellular stores in vascular smooth muscle through 
L-type Ca2+ channels via protein kinase C, it causes Ca2+ influx in the spinal cord neuron 
through N-type Ca2+ channels via protein kinase A.18,19,85  
 
Plasma U-II levels in human diseases 
U-II circulates in human plasma and its plasma level is elevated in renal failure6, congestive 
heart failure23,86,87,88,89, diabetes mellitus7, systemic hypertension90 and portal hypertension 
caused by liver cirrhosis91 (Table 2). 
 
Renal dysfunction 
The plasma U-II concentration is 2-fold higher in patients with renal dysfunction not on 
haemodialysis and 3-fold higher in patients on haemodialysis compared to healthy 
individuals.6 Although there is no correlation between blood pressure and urinary U-II level, 
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a higher urinary U-II level was observed in patients with essential hypertension, patients with 
both glomerular disease and hypertension, and patients with renal tubular disorders, but not in 
normotensive patients with glomerular disease.5 Abundant U-II-like immunoactivity is 
observed in the distal convoluted tubules and the epithelial cells of tubules and ducts in the 
normal kidney as well as renal clear-cell carcinoma.73 
 
In Type 2 diabetic patients, plasma and urinary U-II levels are higher in those with renal 
dysfunction than those with normal renal function.92 This may be due to increased production 
of U-II by various organs as well as by renal tubular cells as a result of renal damage.5,6 In 
diabetic nephropathy, there are dramatic increases in the expressions of U-II and UT receptor 
in the tubular epithelial cells.93 
 
Diabetes 
The elevation in plasma U-II level in diabetic patients is independent of the level of blood 
glucose.7 Insulin secretion in the rat pancreas in response to glucose and arginine can be 
inhibited by U-II.94,95 A single nucleotide polymorphism (SNP) at rs228648 (T21M) in the 
UTS2 gene is correlated with genetic susceptibility to type 2 diabetes in Han people.96 It is 
noteworthy that the SNP at rs2890565 (S89N) has been associated with increased insulin 
resistance and susceptibility of developing type 2 diabetes in Japaneses.97,98  
 
Systemic hypertension 
As U-II is a potent vasoconstrictor, its role in hypertension is worthy of investigation. In the 
anaesthetised cat, intravenous administration of hU-II induces a classical systemic 
hypertensive response with increases in mean blood pressure and systemic vascular 
resistance.68 In a small pilot study, 10 normotensive and 10 hypertensive patients have similar 
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cerebrospinal fluid (CSF) and plasma concentrations of U-II, although the average mean 
arterial blood pressure and CSF U-II concentration show a positive correlation in the 
hypertensive patients.99 However, in a study of 62 hypertensive patients and 62 normotensive 
sex-age-matched controls, plasma urotensin II level is raised in hypertensive patients 
compared to normotensive controls and is directly related to the systolic blood pressure.90 
 
Pulmonary hypertension 
Since endothelial dysfunction has a central role in the initiation and progression of pulmonary 
hypertension, the vasoconstricting effect of U-II on pulmonary artery may be unmasked in 
pulmonary hypertension.50,100 In rats with pulmonary hypertension, U-II-like 
immunoreactivity levels in pulmonary artery endothelial and smooth muscles cells are 
raised.101 In chronic hypoxic rats that have pulmonary hypertension and right ventricular 
hypertrophy, there is up-regulation of UT receptor in the right ventricle.102 At present, not 
much is known about the role of U-II in human pulmonary hypertension. Bosentan, an ET-1 
antagonist, has been used for the treatment of human pulmonary hypertension with 
considerate success. It would be of interest to study if modulation of U-II is of benefit in 
patients with pulmonary hypertension. 
 
Atherosclerosis 
There is increased expression of U-II in atherosclerotic carotid arteries and aortae.9 The 
observation of U-II-like immunoreactivity in the lipid-laden smooth muscle and macrophage-
rich regions of in human coronary atherosclerotic plaque suggests a role of U-II in the 
development of atherosclerosis.2 U-II acts synergistically with mildly oxidized low density 
lipoprotein in inducing vascular smooth muscle cell (VSMC) proliferation.103 Serotonin (5-
HT), contained in platelets, also interact synergistically with U-II to induce VSMC 
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proliferation that may contribute to the rapid development of atherosclerosis in hypertensive 
vascular disease.104 Thus, U-II expression in atherosclerotic plaques may stimulate VSMC 
proliferation. Moreover, locally released U-II may cause coronary vasoconstriction and 
induce myocardial ischaemia.105 
 
Ischaemic heart disease 
U-II may play a role in myocardial ischaemia and acute myocardial infarction. In the 
myocardium of chronic hypoxic rats, there is increased UT receptor expression.102 There are 
increased expressions of U-II and its receptor in both infarct and noninfarct zones of rat left 
ventricle after myocardial infarction.15 U-II also induces the expression of procollagens α1(I) 
and α2(III) and fibronectin in neonatal cardiac fibroblasts.15  
 
Hypertrophy can be induced by hU-II in vitro in cultured neonatal rat cardiomyocytes.15,106,107 
hU-II stimulates the expression of atrial natriuretic peptide and brain natriuretic peptide, 
protein synthesis and morphological changes in cardiomyocytes.106,107 The hypertrophy of 
cultured cardiomyocytes is enhanced significantly when UT receptor is over-expressed and 
can be inhibited by the UT receptor antagonist, BIM-23127.15,108,109 The hypertrophy of 
cardiac myocytes is mediated by the mitogen-activated protein kinases, ERK1/2 and p38 in 
an epidermal growth factor receptor-dependent signalling pathway.108 It may also be 
mediated by IL-6, the release of which can be stimulated by U-II.109 
 
Heart failure 
U-II is one of several neurohormonal systems activated in congestive heart failure.23,86,87,88,89 
In the diseased hearts of patients with end-stage heart failure, expressions of U-II and its 
receptor are upregulated in cardiomyocytes, endothelial cells and vascular smooth muscle 
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cells.89 U-II is also expressed in macrophages and myofibroblasts in patients with ischaemic 
heart disease and its expression in subendocardial myocytes suggests a role in myocardial 
contractility.89 An inverse correlation is observed between U-II expression or plasma U-II 
and ejection fraction.88,89 In heart failure, U-II may also be elevated in diastolic myocardial 
dysfunction.110 U-II may increase cardiac contractility62 and the peripheral vascular tone.72 
Although increased contractility might be beneficial in the short term, prolonged activation 
might lead to myocardial remodelling. Indeed, U-II induces cardiac fibroblast proliferation, 
increases collagen type I gene expression and decreases matrix metalloproteinase-1 gene 
expression.15,111,112 It is of interest to note that U-II causes vasodilatation in the skin vessels of 
normal healthy subjects but vasoconstriction in heart failure patients, which may due to the 
unmasking of the vasoconstriction effect of U-II in endothelial dysfunction, common in heart 
failure diseases.72  
 
Mitogenesis 
U-II may also act as a growth stimulating factor in tumors in an autocrine/paracrine 
manner.113,114 U-II is mitogenic and induces arterial smooth muscle cell proliferation via the 
RhoA/Rho-kinase pathway.18 There are expressions of U-II and UT receptor in various 
human tumour cell lines, such as T98G glioblastoma cells, IMR-32 neuroblastoma cells, 
BeWo choriocarcinoma cells, SW-13 adrenocortical carcinoma cells, DLD-1 colorectal 
adenocarcinoma cells and HeLa cervical cancer cells.30 Cultured SW-13 adrenocortical 
carcinoma cells secrete adrenomedullin, ET-1 and U-II, all of which can promote tumour cell 
growth.30 Indeed, U-II stimulates the proliferation of cultured SW-13 cells and VMRC-RCW 
human renal carcinoma cells.113 U-II stimulates DNA synthesis in a dose-dependent manner 
and induces c-myc expression in quiescent renal epithelial (LLCPK1) cells.114 
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Therapeutic potential 
A UT receptor antagonist may have clinical use in the treatment of systemic, pulmonary and 
portal hypertension, and cardiac and renal failure. Palosuran is a non-peptide UT receptor 
antagonist. Intravenous administration of palosuran protects against renal ischaemia in a rat 
model46, perhaps by inhibiting U-II mediated renal vasoconstriction. Clinical studies of 
palosuran are now in progress to examine its effect on diabetic nephropathy. 
 
Conclusions 
U-II is the most potent vasoconstrictor known, causing endothelium-independent 
vasoconstriction and endothelium-dependent vasodilatation. There is increasing evidence that 
U-II is associated with cardiovascular diseases, atherosclerosis, diabetes, renal dysfunction 
and hypertension although the results of some studies are ambiguous. More research is 
needed to elucidate the physiology and pathophysiology of U-II and its receptor. The role of 
URP in the cardiovascular and nervous system and its relationship with U-II is worthy of 
investigation. The development of UT receptor antagonists may provide a useful research 
tool as well as a novel treatment for cardiorenal diseases. 
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 Table 1. Amino acid sequences of somatostatin, U-II in different species and URP.  
The conserved amino acid residues are underlined.  The two cysteine residues in U-II and 
URP are linked by a disulphide bond to form a ring structure. U-II: urotensin II; URP: 
urotensin-related peptide 
 
Table 2. Plasma U-II levels in different diseases in man.  
Plasma U-II levels are expressed as mean ± SD or median (ranges). Plasma U-II levels 
originally expressed in pg/ml are converted to pmol/l. 
 
Figure 1. Post-translational processing of the human U-II gene product.  
Alternative splicing of exon 2 produces a 7-amino acid fragment as isoform a and a 34-amino 
acid fragment as isoform b. SP: signal peptide. 
 
Figure 2. The signal transduction pathways involved in vasoconstriction, vasodilatation, 
cell proliferation and hypertrophy caused by urotensin II (U-II).  
In vascular smooth muscle cell (VMSC), U-II binds to a G-protein-coupled UT receptor, 
leading to hydrolysis of phosphatidylinositol 3,4,5-trisphosphate (PIP2) to inositol 3,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) by phospholipase C (PLC). IP3 increases 
the release of Ca2+ from the sarcoplasmic reticulum or endoplasmic reticulum. U-II also 
mediates Ca2+ influx through activation of a voltage-gated Ca2+ channel and a La3+-
sensitive non-selective cation channel. DAG stimulates protein kinase C (PKC) which 
phosphorylates CPI-17 (protein kinase C-potentiated inhibitor protein of 17kDa), 
leading to inhibition of myosin light chain phosphatase (MLCP) which catalyses the 
dephosphorylation of phosphorylated regulatory myosin light chain (MLC-2). Rho 
kinase also inhibits MLCP by phosphorylation. Stimulation of myosin light chain (MLC) 
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kinase by Ca2+-calmodulin complex and inhibition of MLCP leads to increase in 
phosphorylated MLC-2. The increases in phosphorylated MLC-2, intracellular Ca2+ 
and phosphorylation of the actin-binding protein, caldesmon, by extracellular signal-
regulated kinase (ERK) or p38 mitogen-activated protein kinase (p38MAPK) lead to 
contraction of VMSC. In endothelial cells, U-II stimulates the production of 
prostacyclin and nitric oxide (NO) which then diffuses into VMSC, leading to increase 
in cGMP and relaxation of VMSC. U-II also mediates cell proliferation and 
hypertrophy through activation of PKC and ERK 1/2 as well as RhoA and its 
downstream kinase system possibly via guanine nucleotide exchange factor (GEF). 
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 Peptides Amino acid sequence 
Human somatostatin-14 AGCKNFFWKTFTSC 
  
Human/monkey U-II ETPDCFWKYCV 
Mouse U-II   QHGAAPECFWKYCI 
Rat U-II QHGTAPECFWKYCI 
Goby U-II AGTADCFWKYCV 
Dogfish NNFSDCFWKYCV 
Frog U-II AGNLSECFWKYCV 
Porcine U-II(A) GPTSECFWKYCV 
Porcine U-II(A) GPPSECFWKYCV 
  
Human/rat/mouse URP ACFWKYCV 
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 Disease Number of 
subjects 
(control:patient) 
Control 
(pmol/l) 
Patient 
(pmol/l) 
p-value Reference 
Heart failure  
 
 
88:74 1.9 ± 0.9 3.9 ± 1.4 <0.0001 87 
Heart failure 
 
220:126 6.6 (3.1-42.6) 22.1 (3.1-
49.2) 
0.001 86 
 
Congestive heart 
failure 
 
18:21 16.3 ± 4.4 166.2 ± 49.5 <0.001 23 
Renal dysfunction 24:12 4.4 ± 1.0 13.1 ± 3.1 <0.0001 6 
Diabetes mellitus: 
With proteinuria 
Without proteinuria 
 
 
22:6 
22:10 
 
4.4 ± 2.0 
4.4 ± 2.0 
 
7.3 ± 0.9 
7.8 ± 0.6 
 
0.0018 
<0.0001 
 
7 
Cirrhosis and 
portal hypertension 
15:50 2592 (72-
8640) 
8856 (1,152-
29,808) 
<0.001 91 
 
Essential 
hypertension 
62:62 8.8 ± 0.9 13.6 ± 1.4 0.005 90 
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42 aa 34 aa* 37 aa 15 aa 38 aa 
Exon  
1 
Exon  
2 
Exon  
3 
Exon
 4 
Exon 
 5 
UTS2 gene 
 1p36 
Prepro-U-II isoform a 
 
 
  
(139 aa) 
Prepro-U-II isoform b 
(124 aa) 
R84R85 R100R101 R126R127R128L42E43 
H2N 
COOH H2N 
COOH 
Urotensin converting 
Enzyme (UCE) 
SP  
 SP 
 
 
 
 
 UII 
 UII 
R27E28 R69R70 R85R86 R111R112R113
Mature U-II (11 aa) H2N-Glu-Thr-Pro-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val-COOH 
S           S 
 36
Endothelial cell L-arginine + O2 
 37
 
MLC kinase 
 
Vascular smooth 
muscle cell 
PLC 
DAG  +  IP3
PIP2 
[Ca2+]↑ 
Ca2
Contraction 
PKC 
CPI-17 CPI-17 
MLCP (active) (inactive) MLCP 
Rho kinase 
MLC-2 MLC-2 caldesmon P
ERK 1/2 and p38MAPK 
ERK1/2 
Proliferation/hypertrophy 
RhoA 
Rho kinase 
Transcription/ 
translation 
U-II 
UT receptor 
NO synthase UT receptor 
L-citrulline + NO 
PGI2
NO 
Guanylate cyclase 
GTP cGMP 
Relaxation 
P
P
Gαq/11 
P
? GEF 
Ca2+-calmodulin 
caldesmon 
 
